Abstract Body

The mechanisms that allow post-treatment controllers (PTC) to limit viral replication after antiretroviral therapy interruption (ATI) remain unclear. Compared to noncontrollers (NC), we hypothesized that PTC would show greater blocks to HIV transcriptional completion and splicing following ATI.

We measured levels of cell-associated (CA) initiated (TAR), 5′-elongated (Long), mid-elongated (Pol), completed (PolyA), and multiply-spliced (TatRev) HIV RNAs in PBMC (by RT-ddPCR) at Pre-ATI, Early-ATI, and Late-ATI time points in 11 NC and 15 PTC.

Before ATI, PTC showed lower levels of TAR and Pol than NC (P<0.04), and a trend toward lower PolyA (P=0.052), but no difference in TatRev or HIV RNA ratios. The median viral loads (VL) at the Early-ATI visits were 143 and 6856 copies/ml for the PTC and NC, respectively (P=0.0004). From Pre-ATI to Early-ATI, NC had increases in Pol, PolyA, TatRev, and ratios of PolyA/Long (completion) and TatRev/Long (multiple-splicing) [all P<0.008] but not initiated (TAR) HIV transcripts (P=0.64). In contrast, PTC showed increases in Long, Pol, and PolyA (all P<0.03) but no change in TatRev, PolyA/Long, or TatRev/Long from Pre-ATI to Early-ATI. Early after ATI, PTC had lower levels of TAR, Long, Pol, PolyA, and PolyA/Long than NC (all P<0.026) and a trend toward lower TatRev (P=0.056). From Early-ATI to Late-ATI, the median VL and levels of all CA HIV RNAs tended to remain stable or increased in NC. In contrast, PTC showed a trend towards a decrease in median levels of Pol and PolyA from Early-ATI to Late-ATI (P=NS), such that there were no significant differences in any CA HIV RNA between Pre-ATI and Late-ATI. At the Late-ATI time point, PTC had lower VL (median 108 vs 11443 copies/ml) than NC and lower TAR, Long, Pol, PolyA, TatRev, PolyA/Long, and TatRev/PolyA (all P<0.05).

In NC, the transition from suppressive ART to viremia is mediated by increases in HIV transcriptional completion and splicing, not initiation. Compared to NC, PTC have lower levels of initiated HIV transcripts prior to ATI and are better able to limit HIV transcriptional completion and splicing after ATI. PTC may also have a decrease in completed HIV transcripts that begins early after ATI, suggesting an immune response targeting cells with completed HIV transcripts. Future strategies aimed at functional cure will likely need to limit HIV transcriptional completion and multiple splicing after ATI.